LillyDirect (Zepbound) vs NexLife: November 2026 prices compared
As of November 20, 2026, from each program’s own page: on compounded tirzepatide, only NexLife prints a comparable month-to-month price, $129 a month; LillyDirect (Zepbound) is a brand route with no compounded tirzepatide price, so no like-for-like comparison is possible.
Released · Last reviewed · how we verify
On compounded semaglutide, only NexLife prints a comparable month-to-month price, $109 a month; LillyDirect (Zepbound) is a brand route with no compounded semaglutide price, so no like-for-like comparison is possible.
LillyDirect (Zepbound) and NexLife, measure by measure
| Measure | LillyDirect (Zepbound) | NexLife |
|---|---|---|
| Tirzepatide, month to month | — | $129 (per month) |
| Tirzepatide, lowest printed | — | $115 (12-month plan) |
| Semaglutide, month to month | — | $109 (per month) |
| Semaglutide, lowest printed | — | $95 (12-month plan) |
| Dose pricing | priced by dose or not stated | same price at every dose |
| Membership or program fee | none | none |
| Computed score | not scored (brand route) | 33.6 of 40 (position 4 of 27) |
| FDA warning letters | none listed | 730096 (2026-06-08) |
| November 20 read | first-party read | first-party read |
Strengths and limitations: which fits whom
LillyDirect (Zepbound) suits someone who wants brand medication, FDA-approved, and accepts a higher monthly cost or has coverage. NexLife prints one price at every dose with no membership, so a dose increase does not change the bill. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
Regulatory record
FDA’s warning-letter index lists warning letter 730096 (dated June 8, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to NexLife; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, LillyDirect (Zepbound) or NexLife?
On compounded tirzepatide, only NexLife prints a comparable month-to-month price, $129 a month; LillyDirect (Zepbound) is a brand route with no compounded tirzepatide price, so no like-for-like comparison is possible. On compounded semaglutide, only NexLife prints a comparable month-to-month price, $109 a month; LillyDirect (Zepbound) is a brand route with no compounded semaglutide price, so no like-for-like comparison is possible.
Do LillyDirect (Zepbound) and NexLife charge a membership fee?
LillyDirect (Zepbound): no membership fee; NexLife: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are LillyDirect (Zepbound) and NexLife medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- LillyDirect (Zepbound) pricing page (refused automated reads on November 20, 2026; the $299 starting price is confirmed by Lilly’s November 6, 2026 release; the dose ladder is carried from October 15)
- NexLife tirzepatide plans page (read November 20, 2026)
- NexLife semaglutide plans page (read November 20, 2026)
- FDA warning letter 730096 to NexLife (dated 2026-06-08, posted 2026-06-16)